Wall Street brokerages expect Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings of $2.55 per share for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Thermo Fisher Scientific’s earnings, with the lowest EPS estimate coming in at $2.52 and the highest estimate coming in at $2.60. Thermo Fisher Scientific posted earnings of $2.31 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.4%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, October 24th.

On average, analysts expect that Thermo Fisher Scientific will report full-year earnings of $10.98 per share for the current financial year, with EPS estimates ranging from $10.93 to $11.09. For the next financial year, analysts forecast that the company will report earnings of $12.27 per share, with EPS estimates ranging from $12.00 to $12.66. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 25th. The medical research company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.63 by $0.12. Thermo Fisher Scientific had a return on equity of 16.28% and a net margin of 10.36%. The firm had revenue of $6.08 billion for the quarter, compared to analyst estimates of $5.90 billion. During the same quarter in the prior year, the company earned $2.30 EPS. Thermo Fisher Scientific’s revenue was up 21.8% on a year-over-year basis.

A number of research firms recently issued reports on TMO. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $233.00 to $242.00 and gave the company an “overweight” rating in a research note on Thursday, July 26th. Leerink Swann upped their target price on Thermo Fisher Scientific from $239.00 to $255.00 and gave the company an “outperform” rating in a research note on Thursday, July 26th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a $300.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 26th. Finally, ValuEngine raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, July 24th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Thermo Fisher Scientific has an average rating of “Buy” and an average target price of $239.08.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 45,000 shares of the business’s stock in a transaction on Friday, June 15th. The stock was sold at an average price of $214.80, for a total value of $9,666,000.00. Following the completion of the transaction, the chief executive officer now directly owns 315,122 shares in the company, valued at approximately $67,688,205.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, June 4th. The shares were sold at an average price of $212.00, for a total value of $530,000.00. The disclosure for this sale can be found here. Insiders sold a total of 168,050 shares of company stock valued at $37,585,029 over the last quarter. 0.49% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Thermo Fisher Scientific by 4.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 6,497 shares of the medical research company’s stock worth $1,341,000 after buying an additional 302 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Thermo Fisher Scientific by 0.3% during the 1st quarter. Wells Fargo & Company MN now owns 3,198,908 shares of the medical research company’s stock worth $660,446,000 after buying an additional 9,820 shares during the last quarter. Tower Bridge Advisors increased its holdings in shares of Thermo Fisher Scientific by 28.5% during the 1st quarter. Tower Bridge Advisors now owns 31,314 shares of the medical research company’s stock worth $6,465,000 after buying an additional 6,950 shares during the last quarter. Daiwa Securities Group Inc. increased its holdings in shares of Thermo Fisher Scientific by 10.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 47,700 shares of the medical research company’s stock worth $9,848,000 after buying an additional 4,606 shares during the last quarter. Finally, S&CO Inc. increased its holdings in Thermo Fisher Scientific by 2.2% in the 1st quarter. S&CO Inc. now owns 50,377 shares of the medical research company’s stock valued at $10,401,000 after purchasing an additional 1,090 shares in the last quarter. Institutional investors own 85.69% of the company’s stock.

TMO stock traded down $0.79 on Friday, reaching $230.00. The company had a trading volume of 1,050,900 shares, compared to its average volume of 1,431,073. Thermo Fisher Scientific has a 1 year low of $172.15 and a 1 year high of $236.29. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.58. The firm has a market cap of $93.22 billion, a P/E ratio of 24.25, a PEG ratio of 1.69 and a beta of 1.13.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 15th. Shareholders of record on Monday, September 17th will be issued a $0.17 dividend. The ex-dividend date of this dividend is Friday, September 14th. This represents a $0.68 annualized dividend and a yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 7.17%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: Price to Earnings Ratio (PE), For Valuing Stocks

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.